For context,1 in 10individuals will develop eczema during their lifetime, while1%of the population suffers from vitiligo.
According to Thibaud Portal, Alys COO, the company doesnt target a share of existing markets.
New dermatology products will grow the market, hetoldthe Financial Times.
We can address the huge number of patients who are currently without treatment.
Over the next three years, the startup aims to deliver proof-of-concept results for seven to ten skin treatments.
Story byIoanna Lykiardopoulou
Ioanna is a writer at TNW.
With a background in the humanities, she has a soft spot for social impact-enabling technologies.
